Evinacumab | m-entrepreneurship.com

Product Name :
Evinacumab

Search keywords :
Evinacumab

drugId :
null

Target Vo:
Angiopoietin like 3

Target Vo Short Name :
ANGPTL3

Moa_Name:
Angiopoietin like 3 inhibitors

First Approval Country :
United States

First Approval Date Filter:
2021

Origin Company_Name :
Regeneron Pharmaceuticals Inc

Active Company_Name :
Regeneron Pharmaceuticals Inc

Active Indication_Name:
Homozygous familial hypercholesterolemia

In Active Indication_Name:
Metabolic Diseases

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Andecaliximab Purity
Naptumomab supplier
Cyclin D1 Antibody (YA485): Cyclin D1 Antibody (YA485) is a non-conjugated and Rabbit origined monoclonal antibody about 34 kDa, targeting to Cyclin D1. It can be used for WB,ICC/IF,IHC-P,IP assays with tag free, in the background of Human, Mouse, Rat.

Author: Betaine hydrochloride

Related Posts